Gene expression profiling of plasma cells and plasmablasts: Toward a better understanding of the late stages of B-cell differentiation

Blood

Volumn 102, Issue 2, 2003, Pages 592-600

  Tarte, Karin ^c   Zhan, Fenghuang ^c   De Vos, John ^c   Klein, Bernard ^a   Shaughnessy Jr , John ^b  

^a INSERM   (France)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BLAST CELL; BONE MARROW CELL; CELL COUNT; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; COMPARATIVE STUDY; DNA MICROARRAY; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENVIRONMENT; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMA CELL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PURIFICATION; STATISTICAL ANALYSIS; STROMA; STRUCTURE ANALYSIS; TONSIL CELL; UNINDEXED SEQUENCE;

EID: 0037818485     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3161     Document Type: Article

References (69)

1. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363-372.
2. O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med. 2002;195:737-745.
3. Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol. 2002;32:923-927.
4. Sze DM, Toellner KM, Garcia de Vinuesa C, Taylor DR, MacLennan IC. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med. 2000;192:813-821.
5. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001;2:1103-1108.
6. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires transcription factor XBP-1. Nature. 2001;412:300-307.
7. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol. 2000;165:5462-5471.
8. Turner CA, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994;77:297-306.
9. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17:51-62.
10. Lin KI, Lin Y, Calame K. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol. 2000;20:8684-8695.
11. Piskurich JF, Lin K, Lin Y, Wang Y, Ting JPY, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol. 2000;1:526-532.
12. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of pax-5 is required for differentiation of B cells to immunoglobulin m-secreting plasma cells. Mol Cell Biol. 2002;22:4771-4780.
13. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity. 2001;14:779-790.
14. Pernis AB. The role of IRF-4 in B and T cell activation and differentiation. J Interferon Cytokine Res. 2002;22:111-120.
15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
16. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
17. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
18. Feldhahn N, Schwering I, Lee S, et al. Silencing of B cell receptor signals in human naive B cells. J Exp Med. 2002;196:1291-1305.
19. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood. 2002;99:2154-2161.
20. Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood. 2002;100:2175-2186.
21. Zhan F, Hardin J, Bumm K, et al. Molecular profiling of multiple myeloma. Blood. 2002;99:1745-1757.
22. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21:6848-6857.
23. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J. Profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003;101:1128-1140.
24. Tarte K, de Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002;100:1113-1122.
25. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput. 2000:455-466.
26. Crescenzi M, Giuliani A. The main biological determinants of tumor line taxonomy elucidated by a principal component analysis of microarray data. FEBS Lett. 2001;507:114-118.
27. Bjorck P, Axelsson B, Paulie S. Expression of CD40 and CD43 during activation of human B lymphocytes. Scand J Immunol. 1991;33:211-218.
28. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000;95:610-618.
29. + hematopoietic progenitor cells. Blood. 1996;87:2632-2640.
30. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood. 2001;97:1817-1822.
31. Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood. 1999;94:701-712.
32. Hauser AE, Debes GF, Arce S, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol. 2002;169:1277-1282.
33. Meraro D, Hashmueli S, Koren B, et al. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J Immunol. 1999;163:6468-6478.
34. Kuo SS, Mellentin JD, Copeland NG, Gilbert DJ, Jenkins NA, Cleary ML. Structure, chromosome mapping, and expression of the mouse Lyl-1 gene. Oncogene. 1991;6:961-968.
35. Juwana JP, Henderikx P, Mischo A, et al. EB/RP gene family encodes tubulin binding proteins. Int J Cancer. 1999;81:275-284.
36. Jung J, Choe J, Choi YS. Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10. Eur J Immunol. 2000;30:2437-2443.
37. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc Natl Acad Sci U S A. 1998;95:189-194.
38. Kee BL, Rivera RR, Murre C. Id3 inhibits B lymphocyte progenitor growth and survival in response to TGF-beta. Nat Immunol. 2001;2:242-247.
39. Cella M, Dohring C, Samaridis J, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med. 1997;185:1743-1751.
40. Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 2002;3:237-243.
41. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323-370.
42. Rissoan MC, Duhen T, Bridon JM, el al. Substractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and three novel transcripts in human plasmacytoid dendritic cells. Blood. 2002;100:3295-3303.
43. Agematsu K, Nagumo H, Oguchi Y, et al. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood. 1998;91:173-180.
44. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331-1339.
45. Vanderkerken K, Broek IV, Eizirik DL, et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis. 2002;19:87-90.
46. Katagiri M, Hakeda Y, Chizaku D, et al. Mechanism of stimulation of osteoclastic bone resorption through gas6/tyro3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol Chem. 2001;276:7376-7382.
47. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-1508.
48. Furuyama N, Fujisawa Y. Distinct roles of cathepsin K and cathepsin L in osteoclastic bone resorption. Endocr Res. 2000;26:189-204.
49. Delaisse JM, Engsig MT, Everts V, et al. Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta. 2000;291:223-234.
50. Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997;90:1649-1655.
51. Choi SJ, Reddy SV, Devlin RD, et al. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem. 1999;274:27747-27753.
52. Johansson L, Grubb A, Abrahamson M, et al. A peptidyl derivative structurally based on the inhibitory center of cystatin C inhibits bone resorption in vitro. Bone. 2000;26:451-459.
53. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol. 2000;111:626-634.
54. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250-2258.
55. Klein U, Gloghini A, Gaidano G, et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood. 2003;101:4115-4121.
56. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837-1851.
57. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood. 1998;92:3189-3202.
58. Wang S, Krinks M, Lin K, Luyten FP, Moos M Jr. Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell. 1997;88:757-766.
59. van der Voort R, Keehnen RM, Beuling EA, Spaargaren M, Pals ST. Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans. J Exp Med. 2000;192:1115-1124.
60. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99:1405-1410.
61. Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277:35990-35998.
62. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol Cell Biol. 1999;19:1171-1181.
63. Nandrot E, Dufour EM, Provost AC, et al. Homozygous deletion in the coding sequence of the c-mer gene in RCS rats unravels general mechanisms of physiological cell adhesion and apoptosis. Neurobiol Dis. 2000;7:586-599.
64. Lataillade JJ, Clay D, Bourin P, et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. Blood. 2002;99:1117-1129.
65. Puthier D, Pellat-Deceunynck C, Barille S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia. 1999;13:289-294.
66. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
67. Ludwig S, Engel K, Hoffmeyer A, et al. 3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol. 1996;16:6687-6697.
68. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000;14:6-16.
69. Raaphorst FM, van Kemenade FJ, Fieret E, et al. Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol. 2000;164:1-4.